Scandion Oncology As Stock Fundamentals
| SCOL Stock | SEK 0.07 0 4.90% |
Scandion Oncology AS fundamentals help investors to digest information that contributes to Scandion Oncology's financial success or failures. It also enables traders to predict the movement of Scandion Stock. The fundamental analysis module provides a way to measure Scandion Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scandion Oncology stock.
Scandion |
Scandion Oncology AS Company Return On Equity Analysis
Scandion Oncology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Scandion Oncology Return On Equity | -0.74 |
Most of Scandion Oncology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scandion Oncology AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Scandion Oncology AS has a Return On Equity of -0.7402. This is 96.91% lower than that of the Healthcare sector and 97.97% lower than that of the Biotechnology industry. The return on equity for all Sweden stocks is 138.77% higher than that of the company.
Scandion Oncology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Scandion Oncology's current stock value. Our valuation model uses many indicators to compare Scandion Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Scandion Oncology competition to find correlations between indicators driving Scandion Oncology's intrinsic value. More Info.Scandion Oncology AS is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Scandion Oncology's earnings, one of the primary drivers of an investment's value.Scandion Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scandion Oncology's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Scandion Oncology could also be used in its relative valuation, which is a method of valuing Scandion Oncology by comparing valuation metrics of similar companies.Scandion Oncology is currently under evaluation in return on equity category among its peers.
Scandion Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | 473.28 % | |||
| Current Valuation | (6.85 M) | |||
| Shares Outstanding | 40.71 M | |||
| Shares Owned By Insiders | 1.82 % | |||
| Price To Book | 1.01 X | |||
| Price To Sales | 969.63 X | |||
| Gross Profit | (32.32 M) | |||
| EBITDA | (55.84 M) | |||
| Net Income | (51.7 M) | |||
| Cash And Equivalents | 131.54 M | |||
| Cash Per Share | 4.09 X | |||
| Current Ratio | 13.92 X | |||
| Book Value Per Share | 2.10 X | |||
| Cash Flow From Operations | (49.8 M) | |||
| Earnings Per Share | (1.74) X | |||
| Target Price | 3.87 | |||
| Number Of Employees | 14 | |||
| Beta | 0.48 | |||
| Market Capitalization | 111.79 M | |||
| Total Asset | 116.22 M | |||
| Net Asset | 116.22 M |
About Scandion Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scandion Oncology AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scandion Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scandion Oncology AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Scandion Oncology AS, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. The company was founded in 2017 and is based in Copenhagen, Denmark. Scandion Oncology operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.